Table 2.

Unadjusted rate of incident diabetes, coronary heart disease, myocardial infarction, sudden death, and stroke associated with androgen deprivation therapy (ADT)^*

	Incident diabetes		Incident CHD		Myocardial infarction		Sudden cardiac death		Stroke
Treatment	Rate (95% CI)	P value†	Rate (95% CI)	P value†	Rate (95% CI)	P value†	Rate (95% CI)	P value†	Rate (95% CI)	P value†
No ADT	87.5 (84.6 to 90.4)	—	81.4 (78.7 to 84.2)	—	7.3 (6.4 to 7.9)	—	11.5 (10.7 to 12.3)	—	10.8 (10.0 to 11.5)	—
GnRH agonist	159.4 (150.6 to 168.3)	<.001	144.0 (135.7 to 152.2)	<.001	12.8 (11.1 to 14.4)	<.001	21.6 (19.4 to 23.7)	<.001	18.5 (16.5 to 20.5)	<.001
Orchiectomy	190.4 (137.6 to 243.2)	<.001	210.5 (150.9 to 270.0)	<.001	24.3 (12.4 to 36.3)	.005	23.3 (11.5 to 35.1)	.05	26.2 (13.8 to 38.7)	.015
Combined androgen blockade	144.6 (117.2 to 172.0)	<.001	157.7 (129.4 to 186.0)	<.001	10.2 (5.2 to 15.2)	.26	20.1 (13.0 to 27.2)	.02	14.8 (8.8 to 20.9)	.19
Oral antiandrogen	126.8 (82.9 to 170.8)	.08	143.2 (97.1 to 189.4)	.009	11.2 (2.3 to 20.1)	.40	18.8 (7.2 to 30.5)	.22	14.9 (4.6 to 25.2)	.43

^*CHD = coronary heart disease; GnRH = gonadotropin-releasing hormone; Rate = number of events per 1000 person-years.

^†P values were based on two-sample z tests that evaluated whether the rate of each outcome for men during treatment with any of the treatments differed from the rate under no androgen deprivation therapy, accounting for censoring. Patients with prevalent diabetes and coronary heart disease did not contribute data to the rates for incident diabetes and coronary heart disease, respectively. All statistical tests were two-sided.